Receptor Tyrosine Kinases as Therapeutic Targets in Rhabdomyosarcoma

Table 2

Clinical trials evaluating drugs that target RTKs or their ligands, with strata that include rhabdomyosarcoma.

RMS tumor eligibility	Patient age (years)	Drug	Intended RMS Target	Additional Targets	Phase	Start date	Sponsor/ collaborator
Small molecule inhibitors
Relapsed/refractory	≥15	Imatinib	PDGFR	ABL, c-Kit	I/II	Aug 2000	EORTC
Resistant	≥15 but ≤70	Imatinib	PDGFR	ABL, c-Kit	II	Feb 2001	Novartis
Advanced	≥10	Imatinib	PDGFR	ABL, c-Kit	II	Jun 2002	NCI
Refractory	≤21	Erlotinib	EGFR		I	Feb 2004	COG/NCI
Refractory	≤21	Gefitinib	EGFR		I	Sep 2005	St. Jude’s/Astra Zeneca
Metastatic/advanced/ recurrent	≥18	Sunitinib	PDGFR	c-KIT, VEGFR2, FLT3	II	Apr 2007	MSKCC/NCI
Advanced	≥13	Dasatinib	SRC	ABL, c-KIT, EPHA2, PDGFR	II	May 2007	SARC/; Bristol-Myers Squibb
Metastatic/recurrent	≥1 but ≤25	Dasatinib	SRC	ABL, c-KIT, EPHA2, PDGFR	I/II	Sep 2008	Beckman Research Institute/; NCI
Metastatic/relapsed/ refractory	≥18	Pazopanib	VEGFR1-3	PDGFR, c-KIT	III	Oct 2008	EORTC
Refractory/recurrent	≥2 but ≤18	Cediranib	VEGFR1-3		I	Dec 2008	NCI
Monoclonal antibodies against RTK ligands
Metastatic	≥0.5 but ≤18	Bevacizumab	VEGF	N/A	II	Jul 2008	Hoffman-La Roche
Monoclonal antibodies against RTKs
Recurrent/refractory	≥2	R1507	IGF-1R	N/A	II	Nov2007	Hoffmann-La Roche/SARC
Unresectable/locally advanced/ metastatic	≥16	IMC-A12	IGF-1R	N/A	I/II	Jun 2008	U. Chicago/NCI
Metastatic/advanced	≥12	IMC-A12	IGF-1R	N/A	II	Jun 2008	ImClone LLC
Relapsed/refractory	≤30	Cixutumumab	IGF-1R	N/A	II	Jan 2009	COG/NCI
Metastatic	≤49	Cixutumumab	IGF-1R	N/A	Pilot	Jan 2010	COG/NCI

Obtained from clinicaltrials.gov website September 2010.